Intermittent fasting in heart failure with preserved ejection fraction

Intermittent fasting in heart failure with preserved ejection fraction - INTERFAST-PRESERVED

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00028261

Enrollment

Registered

2022-10-18

Start date

2023-01-15

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I50

Interventions

Group 1: Intermittent fasting (16/8) for 6 month with cross-over option to Arm 2 (ad libitum) after the first 3 month Group 2: Ad libitum diet for 6 month with cross-over option to Arm 1 (Intermittent

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Written informed consent; chronic heart failure (NYHA II-IV) with preserved ejection fraction (HFA-PEFF-Score =5 Punkte)

Exclusion criteria

Exclusion criteria: no written informed consent; not able to give a written informed consent; simultaneously participating in another intervention trial; anti-diabetic therapy with sulfonylurea; pregnancy; employment relationship or any other relationship of dependence with the study site

Design outcomes

Primary

Measure	Time frame
Difference in walking distance in 6-minute-walking-test (6-MWT) after 3 month compared to baseline walking distance in 6-MWT	—

Secondary

Measure	Time frame
Difference in 6-minute walk test (6-MWT) distance at 6 months compared with baseline 6-MWT distance; hospitalization due to heart failure; hospitalization due to any cardiovascular cause; hospitalization due to any cause; death due to any cause; death due to cardiovascular cause; quality of life (assessed by the Short Kansas Cardiomyopathy Questionnaire, KCCQ-12); hypoglycemia; body weight; BMI; waist-to-hip ratio; blood pressure; (pre)medication; comorbidities (esp. diabetes mellitus); echocardiographic parameters (e.g. e', E/e', LAVI, TR velocity, GLS, LVMI, RWT, IVSd, electromechanical delay, LA strain); endothelial function (via pulse amplitude tonometry); Laboratory parameters (hGH, adiponectin, NT-proBNP, creatinine, fasting insulin, fasting blood glucose, HbA1c, differential blood count, IL-6, C-reactive protein, homocysteine, cholesterol, LDL, HDL, triglycerides); circulating immune cells; DNA methylation of circulating cells ("epigenetic clock").	—

Measure

Time frame

Difference in 6-minute walk test (6-MWT) distance at 6 months compared with baseline 6-MWT distance; hospitalization due to heart failure; hospitalization due to any cardiovascular cause; hospitalization due to any cause; death due to any cause; death due to cardiovascular cause; quality of life (assessed by the Short Kansas Cardiomyopathy Questionnaire, KCCQ-12); hypoglycemia; body weight; BMI; waist-to-hip ratio; blood pressure; (pre)medication; comorbidities (esp. diabetes mellitus); echocardiographic parameters (e.g. e', E/e', LAVI, TR velocity, GLS, LVMI, RWT, IVSd, electromechanical delay, LA strain); endothelial function (via pulse amplitude tonometry); Laboratory parameters (hGH, adiponectin, NT-proBNP, creatinine, fasting insulin, fasting blood glucose, HbA1c, differential blood count, IL-6, C-reactive protein, homocysteine, cholesterol, LDL, HDL, triglycerides); circulating immune cells; DNA methylation of circulating cells ("epigenetic clock").

—

Countries

Germany

Contacts

Public ContactKai Knöpp

Universitätsklinikum Halle (Saale) Klinik für Innere Medizin III

kai.knoepp@uk-halle.de0345-557-3103

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026